| Literature DB >> 35979346 |
Rui Su1, Huanhuan Yan1, Na Li1, Tingting Ding1, Baochen Li1, Yuhuan Xie1, Chong Gao2, Xiaofeng Li1, Caihong Wang1.
Abstract
Objective: This study aimed to analyze the application value of blood metagenomic next-generation sequencing (mNGS) in patients with connective tissue diseases (CTDs) to provide a reference for infection diagnosis and guidance for treatment.Entities:
Keywords: CMV (citomegalovirus); EBV - Epstein-Barr Virus; connective tissue diseases; infection; metagenomic next-generation sequencing; virus
Mesh:
Year: 2022 PMID: 35979346 PMCID: PMC9376218 DOI: 10.3389/fimmu.2022.939057
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Baseline characteristics of all patients.
| Characteristics and laboratory parameters | All patients | Positive* | Negative |
|
|---|---|---|---|---|
|
| 50.30 ± 16.55 | 52.23 ± 16.72 | 50.00 ± 18.55 | >0.05 |
|
| 99 (78.6) | 79 (73.7) | 20 (87.0) | >0.05 |
|
| 8.60 ± 5.22 | 8.86 ± 5.21 | 8.23 ± 6.60 | >0.05 |
|
| 112.52 ± 22.56 | 114.74 ± 22.66 | 111.38 ± 23.95 | >0.05 |
|
| 228.02 ± 114.00 | 223.21 ± 120.93 | 213.31 ± 89.26 | >0.05 |
|
| 7.64 ± 7.57 | 8.10 ± 9.01 | 8.44 ± 7.50 | >0.05 |
|
| 75.45 ± 16.96 | 75.05 ± 18.86 | 73.21 ± 24.09 | >0.05 |
|
| 1.09 ± 0.74 | 1.12 ± 0.83 | 1.01 ± 0.93 | >0.05 |
|
| 15.97 ± 11.24 | 15.29 ± 10.53 | 15.27 ± 9.66 | >0.05 |
|
| 1.35 ± 10.11 | 0.44 ± 0.25 | 0.40 ± 0.30 | >0.05 |
|
| 75.45 ± 16.97 | 5.80 ± 3.60 | 5.38 ± 2.48 | >0.05 |
|
| 64.47 ± 43.36 | 67.09 ± 42.34 | 53.92 ± 38.99 | >0.05 |
|
| 53.50 ± 67.32 | 61.70 ± 77.87 | 31.82 ± 44.68 | >0.05 |
|
| 2.08 ± 7.04 | 2.41 ± 7.81 | 0.56 ± 0.21 | >0.05 |
|
| 53 | 40 (38.8%) | 13 (56.5%) | >0.05 |
|
| 45 | 33 (32.0%) | 12 (52.2%) | >0.05 |
*The infection group included 98 mNGS positive and 5 only CDT positive. The non-infection group means negative for mNGS and CDT.
Figure 1(A) Distribution of disease types among all enrolled patients. (B) Comparison of test results between mNGS and conventional diagnostic testing methods (CDT) in peripheral blood of patients with CTD. Both+, results of mNGS and CDT were both positive; both-, results of mNGS and CDT were both negative; only mNGS+, only the mNGS result was positive; only conventional testing+, only the CDT result was positive. Match, results of mNGS were totally identical with those of CDT; partly matched, results of mNGS and CDT were totally matched, mNGS often identified more pathogens than conventional methods; mismatch, results of mNGS and CDT were totally mismatched.
Clinical features and complications of all patients.
| Clinical features and complications | Positive* | Negative |
|
|---|---|---|---|
|
| 70 (67.96%) | 14 (60.87%) | 0.514 |
|
| 31 (30.10%) | 1 (4.35%) | 0.009 |
|
| 7 (6.8%) | – | – |
|
| 3 (2.91%) | 2 (8.70%) | 0.199 |
|
| 4 (3.88%) | 1 (4.35%) | 0.918 |
|
| 1 (0.97%) | – | – |
|
| 1 (0.97%) | – | – |
|
| 2 (1.94%) | – | – |
|
| 1 (0.97%) | – | – |
|
| 9 (1.94%) | 1 (4.35%) | 0.481 |
|
| 8 (8.74%) | 2 (8.70%) | 0.882 |
|
| 5 (4.85%) | – | – |
|
| 3 (2.91%) | – | – |
*Positive included 98 mNGS positive and 5 only CDT positive. Negative means negative for mNGS and CDT.
Figure 2Distribution of pathogens detected by mNGS. (A) Type distribution of pathogens identified by mNGS. Species distribution of (B) viruses, (C) prokaryotes, and (D) eukaryotes detected by mNGS.
Figure 3(A) The classification of mixed infections with or without viruses detected by mNGS and conventional diagnostic testing methods (CDT). In the mixed infection, there were 5 cases with no virus infection and 38 cases with virus infection, namely, 20 cases of bacteria and viruses infection; 4 cases of bacteria, fungi, and virus infection; 9 cases of virus mixed infection; 1 case of bacteria, virus, fungi, and mycoplasma infection; 1 case of bacteria, virus, and mycoplasma infection; 1 case of virus and mycoplasma infection, and 1 case of virus and fungi infection. (B) Distribution of pathogens for single infections.